Compounds with anti-KS and anti-HIV activity

Abstract

The present invention relates to a compound having anti-KS and anti-HIV pharmaceutical activity which comprises an HCG-like inhibitory protein and fragments or derivatives thereof, said protein and fragments thereof are isolated from a biologically active fraction of APL-HCG, wherein said protein has a molecular weight of about 3,500 or of about 13,000 Dalton, and wherein said protein and fragments thereof are adsorbed polypropylene plastic supports. A pharmaceutical composition for the prevention and/or treatment of Kaposi's sarcoma (KS) and HIV which comprises an therapeutically effective amount of at least one compound of the present invention in association with a pharmaceutically acceptable carrier. A method for the prevention, treatment and/or reduction of Kaposi's sarcoma and HIV expression in AIDS patients, which consists in administering the composition to the patient.

What is claimed is:  
     
         1 . A plastic-adsorbing compound having anti-KS and anti-HIV pharmaceutical activity which comprises at least one biologically active compound isolated from a biologically active fraction of APL-HCG.  
     
     
         2 . A plastic-adsorbing compound of  claim 1 , wherein said at least one biologically active compound has a molecular weight of less than about 14,000 Dalton.  
     
     
         3 . The plastic-adsorbing compound of  claim 1 , wherein said at least one biologically active compound has an amino acid sequence selected from the group consisting of: 
 Ser-Lys-Glu-Pro-Leu-Arg-Pro-Arg-Glu-Arg-Pro-Ile-Asn*-Ala-Tbr-Leu-Ala-Val-Glu-Lys SEQ ID NO:1; and    Ala-Pro-Asp-Val-Gln-Asp-Lys-Phe-Thr-Arg-Gln-Ile-Met-Ala-Thr SEQ ID NO:2;    and biologically active derivatives and fragments thereof.    
     
     
         4 . The plastic-adsorbing compound of  claim 3 , wherein said derivatives contain one or more D-amino acids or non-natural amino-acids.  
     
     
         5 . A pharmaceutical composition for the prevention and/or treatment of Kaposi's sarcoma (KS) and/or HIV which comprises a therapeutically effective amount of at least one compound of  claim 1 , in association with a pharmaceutically acceptable carrier.  
     
     
         6 . A pharmaceutical composition for the prevention and/or treatment of Kaposi's sarcoma (KS) and/or HIV which comprises a therapeutically effective amount of at least one compound of  claim 3 , in association with a pharmaceutically acceptable carrier.  
     
     
         7 . The pharmaceutical composition of  claim 5 , which is formulated as a controlled release formulation.  
     
     
         8 . A method for the prevention, treatment and/or reduction of Kaposi's sarcoma and/or HIV expression in AIDS patients, which comprises administering to said patients a therapeutically effective amount of a compound of  claim 1 .  
     
     
         9 . A method for the prevention, treatment and/or reduction of Kaposi's sarcoma and/or HIV expression in AIDS patients, which comprises administering to said patient a therapeutically effective amount of a pharmaceutical composition of claim 5 .  
     
     
         10 . A method to purify the compound of  claim 1 , which comprises the steps of: 
 a) subjecting a biologically active fraction of APL-HCG or urinary extract comtaining said compound or protein to a polypropylene plastic support for a time sufficient for adsorption of said compound or protein to occur; and    b) washing the support and releasing the adsorbed compound or protein therefrom.    
     
     
         11 . A method of evaluating biological anti-KS and anti-HIV activity of a polypropylene-adsorbing compound of  claim 1 , which comprises measuring AP1 gene activity.  
     
     
         12 . The method of  claim 11 , wherein measuring of said AP1 gene activity is effected by measuring binding to DNA response element.